PL3740199T3 - Enkapsułkowane polimerem wektory wirusowe do terapii genetycznej - Google Patents

Enkapsułkowane polimerem wektory wirusowe do terapii genetycznej

Info

Publication number
PL3740199T3
PL3740199T3 PL19743691.8T PL19743691T PL3740199T3 PL 3740199 T3 PL3740199 T3 PL 3740199T3 PL 19743691 T PL19743691 T PL 19743691T PL 3740199 T3 PL3740199 T3 PL 3740199T3
Authority
PL
Poland
Prior art keywords
polymer
viral vectors
genetic therapy
encapsulated viral
encapsulated
Prior art date
Application number
PL19743691.8T
Other languages
English (en)
Inventor
Cecile Bauche
Renaud Vaillant
Emeline SARRY
Frederic Mourlane
Philippe BISHOP
Original Assignee
Ixaka France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ixaka France filed Critical Ixaka France
Publication of PL3740199T3 publication Critical patent/PL3740199T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL19743691.8T 2018-01-17 2019-01-17 Enkapsułkowane polimerem wektory wirusowe do terapii genetycznej PL3740199T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862618156P 2018-01-17 2018-01-17
US201862661990P 2018-04-24 2018-04-24
US201862715007P 2018-08-06 2018-08-06
PCT/IB2019/000361 WO2019145796A2 (en) 2018-01-17 2019-01-17 Polymer-encapsulated viral vectors for genetic therapy

Publications (1)

Publication Number Publication Date
PL3740199T3 true PL3740199T3 (pl) 2024-12-16

Family

ID=67394531

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19743691.8T PL3740199T3 (pl) 2018-01-17 2019-01-17 Enkapsułkowane polimerem wektory wirusowe do terapii genetycznej

Country Status (14)

Country Link
US (1) US20200360297A1 (pl)
EP (1) EP3740199B1 (pl)
JP (2) JP2021510548A (pl)
KR (1) KR102812046B1 (pl)
CN (1) CN111902134A (pl)
AU (2) AU2019213290A1 (pl)
BR (1) BR112020014650A2 (pl)
CA (1) CA3088933A1 (pl)
DK (1) DK3740199T3 (pl)
ES (1) ES2991922T3 (pl)
FI (1) FI3740199T3 (pl)
MX (1) MX2021001423A (pl)
PL (1) PL3740199T3 (pl)
WO (1) WO2019145796A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022003407A (es) 2019-09-21 2022-07-04 Ixaka France Síntesis sin dmso de poli(beta-aminoéster)es modificados con oligopéptidos y su uso en sistemas de suministro de nanopartículas.
JP2023502925A (ja) * 2019-11-15 2023-01-26 イグザカ フランス 生体内遺伝子治療のためのポリマー封入ウイルスベクター
WO2021234455A2 (en) 2020-05-19 2021-11-25 Ixaka France Promoter sequences for in vitro and in vivo expression of gene therapy products in cd3+ cells
CN120603955A (zh) * 2022-12-16 2025-09-05 百合治疗股份有限公司 具有工程化功能的病毒载体及其生产方法
WO2024201067A1 (en) * 2023-03-31 2024-10-03 Dawn Therapeutics Limited Transfection system
WO2024233882A1 (en) * 2023-05-11 2024-11-14 Alaya.Bio Inc. Extracellular vesicles for the delivery of payloads to eukaryotic cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1216544A1 (zh) * 2012-12-14 2016-11-18 The Regents Of The University Of California 病毒載體納米膠囊靶向基因治療及其製備
GB201304245D0 (en) 2013-03-08 2013-04-24 Inst Quimic De Sarria Chemical compounds
US20160145348A1 (en) 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
EP3065711B8 (en) * 2013-11-05 2024-10-16 Takara Bio USA, Inc. Dry transfection compositions and methods for making and using the same
WO2015175545A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
EP3511413B1 (en) 2014-07-25 2022-09-07 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
US20170348402A1 (en) * 2014-07-30 2017-12-07 The Research Foundation For The State University Of New York System and method for delivering genetic material or protein to cells
WO2016022947A1 (en) * 2014-08-07 2016-02-11 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
GB201501025D0 (en) 2015-01-21 2015-03-04 Sagetis Biotech Sl Chemical compounds
GB201708203D0 (en) * 2017-05-22 2017-07-05 Sagetis Biotech Sl Chemical compounds

Also Published As

Publication number Publication date
JP2024020452A (ja) 2024-02-14
AU2024259893A1 (en) 2024-11-28
AU2024259893B2 (en) 2026-05-07
AU2019213290A1 (en) 2020-08-06
ES2991922T3 (es) 2024-12-05
US20200360297A1 (en) 2020-11-19
BR112020014650A2 (pt) 2021-02-17
EP3740199A2 (en) 2020-11-25
JP2021510548A (ja) 2021-04-30
WO2019145796A3 (en) 2019-11-07
MX2021001423A (es) 2021-11-17
EP3740199B1 (en) 2024-08-14
CA3088933A1 (en) 2019-08-01
CN111902134A (zh) 2020-11-06
FI3740199T3 (fi) 2024-11-11
WO2019145796A2 (en) 2019-08-01
KR102812046B1 (ko) 2025-05-23
DK3740199T3 (da) 2024-11-11
KR20200128520A (ko) 2020-11-13

Similar Documents

Publication Publication Date Title
EP3645021A4 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
IL284185A (en) Compositions for drg-specific reduction of transgene expression
IL270567B (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
SI3740222T1 (sl) Modificiran kapsidni protein raav za gensko terapijo
EP3558393A4 (en) ADENO-ASSOCIATED VIRAL VECTORS
IL277666A (en) Virus vector evasion antibody
IL286825A (en) Gene therapy for eye pathologies
EP3861130A4 (en) GENETIC MODULATORS
MA47680A (fr) Arn thérapeutique
IL277664A (en) Virus vector evasion antibody
EP3880235A4 (en) GENE THERAPY OF NEURAL ZEROID LIPOFUSCINOSES
IL260796A (en) Optimized factor viii genes
IL272373A (en) Factor viii (fviii) gene therapy methods
EP4051324A4 (en) Gene therapy vectors
IL262211A (en) Gene therapy for treating mucopolysaccharidosis type ii
DK3364997T5 (da) Aspartoacylase genterapi til behandling af canavans sygdom
SI3612624T1 (sl) Genska terapija
DK3137497T4 (da) Aav-vektorer til retinal- og cns-genterapi
SG11202009450SA (en) Virus vectors for targeting ophthalmic tissues
PL3577124T3 (pl) Sól hemisiarczanowa nukleotydu do leczenia wirusowego zapalenia wątroby typu c
IL283496A (en) Gene therapies for neurodegenerative disease
EP3717652A4 (en) GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IIIB
EP3484520A4 (en) STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS
SI3612237T1 (sl) Genska terapija
SG11202009854XA (en) Modified viral capsids